Fred Hutchinson Cancer Rearch Center
United States of America
Dr. Till is an assistant member at Fred Hutch and an assistant professor at UW. He specializes in lymphoma and stem cell transplantation. Dr. Till also conducts research on developing new immunotherapies for lymphoma, with a focus on using patients' own T cells to fight their lymphomas, using genetically engineered cells with chimeric antigen receptors(CARs). Dr. Till earned his M.D. from the University of Chicago, then received internal medicine training with a residency at the University of Pennsylvania. He then came to Seattle to specialize in oncology with a fellowship at Fred Hutch and the UW. He is board certified in medical oncology and is a member of the SWOG national clinical trials group, the American Society of Hematology, the National Cancer Institute Clinical Trials Planning Meetings (Lymphoma Steering Committee). He has received research funding from the American Society of Clinical Oncology, Lymphoma Research Foundation, Damon Runyon Cancer Research Foundation and the National Cancer Institute.
Clinical and laboratory research in CAR T cell therapy (using gene therapy to train patients' immune cells to attack their lymphomas).
James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, et al. Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. Journal of immunology (Baltimore, Md. : 1950) 2010 Apr; 184; 8; 4284-94
Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Aug; 29; 22; 3023-9
Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012 Apr; 119; 17; 3940-50
Till BG, Press OW Depletion of Tregs for adoptive T-cell therapy using CD44 and CD137 as selection markers. Immunotherapy 2012 May; 4; 5; 483-5
Till BG, Madtes DK BCNU-associated pneumonitis: portrait of a toxicity. Leukemia & lymphoma 2012 Jun; 53; 6; 1019-20